Cosmo Pharmaceuticals NV (XSWX:COPN) Total Stockholders Equity : CHF420.7 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV Total Stockholders Equity?

Cosmo Pharmaceuticals NV's Total Stockholders Equity for the quarter that ended in Jun. 2023 was CHF420.7 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cosmo Pharmaceuticals NV's Book Value per Share for the quarter that ended in Jun. 2023 was CHF26.17. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cosmo Pharmaceuticals NV's Debt-to-Equity for the quarter that ended in Jun. 2023 was 0.41.

Cosmo Pharmaceuticals NV Total Stockholders Equity Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Total Stockholders Equity Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Stockholders Equity

Get a 7-Day Free Trial

500.76

429.87

432.45

525.83

450.93

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Stockholders Equity	Get a 7-Day Free Trial															405.78	525.83	474.37	450.93	420.74

Cosmo Pharmaceuticals NV (XSWX:COPN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cosmo Pharmaceuticals NV's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(420.738	-	0)	/	16.076
	=	26.17

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cosmo Pharmaceuticals NV's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(169.893	+	1.358)	/	420.738
	=	0.41

Cosmo Pharmaceuticals NV Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CMOPF:USA COPNz:UK C43:Germany

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines